|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both androgen and RNA-binding protein PSF play a role in the pathology of AD.
|
31541592 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anterior pharynx-defective 1A (APH-1A) is a seven transmembrane component of γ-secretase (GS), an aspartyl protease enzyme involved in the production of toxic amyloid-β peptides in Alzheimer's disease patients.
|
30979338 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of APH-1α/1β and PS1 ultimately determined the production and deposition of β-amyloid protein (Aβ), an effect that potentially contributes to the pathogenesis of AD.
|
30383537 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
γ-Secretase complex, the assembly of nicastrin (NCT), Presenilin (PS), Presenilin Enhancer-2 (PEN-2) and Anterior pharynx defective 1 (Aph-1), catalyzes the cleavage of amyloid precursor protein to generate amyloid-β protein (Aβ), the main culprit of Alzheimer's disease.
|
29787759 |
2018 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To observe the effects of Huannao Yicong Formula (, HYF) on learning and memory and it's regulating effect on γ-secretase related anterior pharynx defective 1 (APH-1), presenilin enhancer-2 (PEN-2) signaling pathway, so as to discuss and further clarify the mechanism of HYF on Alzheimer's disease.
|
28120208 |
2017 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, the induction of APH-1α/1β was confirmed in the brains of patients with AD.
|
27240539 |
2016 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In neurons, ERK1/2 and PPARγ signaling pathways were activated by MgT treatment, which in turn suppressed (by >80%) the expression of APH-1α/-1β, which is responsible for the deposition of Aβ and potentially contributes to the memory deficit that occurs in AD.
|
26293690 |
2015 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two GPCRs implicated previously in Alzheimer's disease (GPR3 and the β(2)-adrenergic receptor) mediate their effects on Aβ generation through interaction with β-arrestin 2. β-arrestin 2 physically associates with the Aph-1a subunit of the γ-secretase complex and redistributes the complex toward detergent-resistant membranes, increasing the catalytic activity of the complex.
|
23202293 |
2013 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We validated the presence of APH-1A promoter polymorphism -980C/G in other two Chinese cohort sets (450 AD and 450 controls).
|
21443683 |
2011 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The senile plaques found in the brains of patients with Alzheimer's disease are mainly due to the accumulation of amyloid beta-peptides (A beta) that are liberated by gamma-secretase, a high molecular weight complex including presenilins, PEN-2, APH-1 and nicastrin.
|
19889971 |
2009 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that polymorphisms in APH-1a/b coding regions are not linked with higher risk for sporadic AD in our Italian population sample.
|
12972157 |
2003 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The OS and PSF were significantly enhanced in patients with lower expression of CD105 in both tumor tissue and PB compared to those with higher expression of CD105 in both tumor tissue and PB (12.4 vs 8.5, P < 0.001, 8.5 vs 6.5, P < 0.001).
|
29799303 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CTBP1-AS also exhibits global androgen-dependent functions by inhibiting tumour-suppressor genes via the PSF-dependent mechanism thus promoting cell cycle progression.
|
23644382 |
2013 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The morphologic and immunohistochemical discrepancies between this intriguing melanotic tumor and other documented renal cell carcinomas bearing identical PSF-TFE3 gene fusion may suggest melanotic Xp11 translocation renal cancer is a distinct entity among the MiT/TFE family neoplasms.
|
19809274 |
2009 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Expression of VL30-1 RNA is 5- to 8-fold higher in mouse tumor lines than in mouse fibroblast or myoblast lines, whereas expression of PSF mRNA does not decrease in the tumor lines, suggesting that tumorigenesis is driven by an increase of VL30-1 RNA rather than a decrease of PSF.
|
19805375 |
2009 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
While PSF can function as a DNA-binding protein with a tumor suppressive function, its association with Hakai promotes PSF's RNA-binding ability and post-transcriptional influence on target mRNAs.
|
19855157 |
2009 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Pazopanib was well tolerated and clinically active, surpassing predefined metrics proposed by the European Organization for Research and Treatment of Cancer indicative of "active" sarcoma drugs (5.63 months progression-free survival [PSF], with 62% of the study population achieving progression-free survival at 12 weeks).
|
29212731 |
2018 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Pazopanib was well tolerated and clinically active, surpassing predefined metrics proposed by the European Organization for Research and Treatment of Cancer indicative of "active" sarcoma drugs (5.63 months progression-free survival [PSF], with 62% of the study population achieving progression-free survival at 12 weeks).
|
29212731 |
2018 |
|
Renal Cell Carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Xp11 translocation renal cell carcinoma (RCC) with SFPQ/PSF-TFE3 gene fusion is a rare epithelial tumor.
|
28315422 |
2017 |
|
Renal Cell Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Secondary PSF/TFE3-associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma.
|
21504709 |
2011 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We conclude that human hPSF-binding RNAs drive transformation and tumorigenesis by reversing PSF-mediated repression of proto-oncogene transcription and that dysfunctional regulation of human hPSF-binding RNA expression has a central role in the etiology of human cancer.
|
19625619 |
2009 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Thus, Hakai can affect the oncogenic phenotype both by altering E-cadherin-based intercellular adhesions and by increasing PSF's ability to bind RNAs that promote cancer-related gene expression.
|
19855157 |
2009 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We propose that PSF protein and PSF-binding RNAs have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer.
|
19805375 |
2009 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
We propose that PSF protein and PSF-binding RNAs have a central role in the reversible regulation of mammalian cell proliferation and tumorigenesis and that increasing PSF expression or decreasing PSF-binding RNA expression in tumor cells is a potential therapeutic strategy for cancer.
|
19805375 |
2009 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF.
|
19855157 |
2009 |